Results 321 to 330 of about 27,710,413 (387)

Chromatin accessibility of circulating CD8⁺ T cells differentiates disease severity in IgA nephropathy. [PDF]

Sci Rep
Kim G, Lee S, Lee S, Shin SK, Park S, Koh JH, Cho S, Kim Y, Kim IS, Lee SJ, Seo C, Lee DS, Kim HR, Shin HM, Kim DK, KORNERSTONE investigators.   +15 more
europepmc   +1 more source

Dynamics of CD40 ligand levels in newly diagnosed and treated tuberculosis patients: An evaluation of sCD40L concentration and CD4⁺ T cell surface expression

Sara Samar, Romeeza Tahir, Victoria Samar, Faheem Shahzad, Muhammad Kashif, Abdul Razzaq, Nadeem Afzal   +6 more
openalex   +1 more source

Immunotoxicity of TCDD: role of Fas expression and MHC phenotype on TCDD-mediated thymic atrophy and decrease in peripheral T cell responsiveness

, 1995
Rhile, Mark Joseph
openalex   +1 more source

The Role and Research Progress of CD8⁺ T Cells in Sepsis. [PDF]

Biomedicines
Wang X, Huang Q, Zuo Z, Wang Z, Zhang L, Qian Z.   +5 more
europepmc   +1 more source

Impact of vector copy number on critical quality attributes of retrovirally engineered T cells. [PDF]

Mol Ther
Norberg SM, Gund R, Doubrovina E, Doran SL, Fuksenko T, Liu H, Ma J, Franco Z, Hinrichs CS.   +8 more
europepmc   +1 more source

Regulatory T cells in cancer: from immunosuppression to therapeutic targeting. [PDF]

Front Immunol
Basurto-Olvera P, Serrano H, Maldonado-Bernal C.   +2 more
europepmc   +1 more source

Cytotoxic CD4+ T cells in cancer: an emerging target for next-generation anticancer immunotherapy? [PDF]

J Immunother Cancer
van Wandeloo IMB, Bol K, van Herpen C, de Vries IJM, Schreibelt G.   +4 more
europepmc   +1 more source

CD4⁺ T cells confer transplantable rejuvenation via Rivers of telomeres

Lanna A, Valvo S, Dustin ML, Rinaldi F.
europepmc   +1 more source

Virus-Specific T Cells and Response to Checkpoint Inhibitors in Progressive Multifocal Leukoencephalopathy.

JAMA Neurol
Möhn N, Grote-Levi L, Bonifacius A, Tischer-Zimmermann S, Nay S, Jendretzky KF, Sassmann ML, Karacondi K, Zent M, Konen FF, Sühs KW, Meuth SG, Pawlitzki M, Warnke C, Ayzenberg I, Schneider R, Helmchen C, Brüggemann N, Klebe S, Hildner M, Grefkes C, Nitsch L, Hühnchen P, Böltz S, Alt L, Tumani H, Kleinschnitz C, Pul R, Grauer O, Clifford D, Gnanapavan S, Wicklein R, Perpoint T, Beudel M, Del Bello A, Rauer S, Wiendl H, Jelcic I, Gasnault J, Cimini E, Antinori A, Pinnetti C, Pourcher V, Weiss N, Lambert N, Maecker-Kolhoff B, Höglinger GU, Zahraeifard S, Cortese I, Eiz-Vesper B, Martin-Blondel G, Skripuletz T, Immunotherapy for PML Study Group.   +52 more
europepmc   +1 more source